Anti/Proapoptotic ratio and cell preservation efficacy

简介（由申请人提供）：BioLife Solutions Inc是一家成立于1998年的生物技术公司，研发和公司总部位于纽约宾厄姆顿的纽约州立大学公园。BioLife开发了两种不同的冷藏保存解决方案，用于改善人类细胞、组织和器官的时间管理、运输和储存。BioLife的HypoThermosol （HTS）平台专为低温保存（4℃至8℃）而设计；而BioLife的CryoStor平台是为改进人类细胞的低温保存（-196℃）而设计的。公司通过以下方式产生收入：(1)通过其合同制造商和非独家分销商MediaTech进行销售；(2)直接从公司总部进行销售；(3)执行按服务付费合同，即各生物技术公司与BioLife签订合同，开发优化的解决方案和协议。BioLife通过研究长时间冷藏导致细胞死亡的分子细节，优化了HTS和CryoStor溶液的性能。因此，HTS比其主要竞争对手ViaSpan要好好几倍；而CryoStor作为一种低温保存剂，使用低水平的DMSO与传统的解决方案相比，效果要好得多。这项I期研究提出的数据表明，bcl-2抗凋亡蛋白家族可能对改善低温和低温保存很重要。BioLife计划使用一些与器官移植和组织工程相关的细胞和组织来确定这些bcl-2家族成员蛋白的变化是否与保存效果有关。在I期提案中产生的数据将允许BioLife确定在II期提出的未来保存溶液优化是否应该面向调节抗凋亡蛋白bcl-2家族以提高细胞保存效果。

DESCRIPTION (provided by applicant): BioLife Solutions Inc is a biotechnology company that was incorporated in 1998 with R&D and corporate headquarters at SUNY Park in Binghamton, New York. BioLife has developed two different families of cold-storage preservation solutions for the improved time management, shipping and storage of human cells, tissues and organs. BioLife's HypoThermosol (HTS) platform is designed for hypothermic preservation (4 C to 8 C); whereas BioLife's CryoStor platform is designed for the improved cryopreservation (-196 C) of human cells. The Company generates revenues through (1) sales through its contract manufacturer and non-exclusive distributor, MediaTech, (2) sales directly from the Company headquarters and (3) the execution of pay-for-services contracts whereby individual biotechnology companies contract BioLife to develop optimized solutions and protocols. BioLife has optimized the performance of both the HTS and CryoStor solutions through studying the molecular details of cell death that occur due to extended cold-storage. As a consequence, HTS is up to severalfold better than its leading competitor, ViaSpan; whereas, CryoStor is significantly better as a cryopreservation agent using reduced levels of DMSO compared to traditional solutions. This Phase I proposal presents data that suggest that the bcl-2 antiapoptotic family of proteins may be important to improved hypothermic and cryopreservation. BioLife plans to use a number of cells and tissues relevant to organ transplants and tissue engineering to determine if there is a correlation in the change of any of these bcl-2 family member proteins and the efficacy of preservation. The data generated in the Phase I proposal will allow BioLife to determine if future preservation solution optimization to be proposed in Phase II should be geared toward regulating the bcl-2 family of antiapoptotic proteins to improve cell preservation efficacy.